3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2‘:5,6]pyrido[4,3-d]pyrimidin-2-one | 1513859-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3‘,2‘:5,6]pyrido[4,3-d]pyrimidin-2-one
• 英文别名: 11-(2,6-Difluoro-3,5-dimethoxyphenyl)-13-[(3-fluorophenyl)methyl]-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one；11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-[(3-fluorophenyl)methyl]-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
• CAS: 1513859-69-2
• 化学式: C₂₄H₁₉F₃N₄O₃
• 分子量: 468.435
• InChiKey: ASEOWXFORSTMEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170137424A1

  公开（公告）日：2017-05-18

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及三环化合物以及其药物组成物，它们是一种或多种FGFR酶的抑制剂，可用于治疗与FGFR相关的疾病，如癌症。
• Substituted tricyclic compounds as FGFR inhibitors
  申请人：Incyte Corporation

  公开号：US11053246B2

  公开（公告）日：2021-07-06

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及三环化合物及其药物组合物，它们是一种或多种表皮生长因子受体酶的抑制剂，可用于治疗表皮生长因子受体相关疾病，如癌症。
• US9611267B2
  申请人：——

  公开号：US9611267B2

  公开（公告）日：2017-04-04
• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR
  申请人：INCYTE CORP

  公开号：WO2014007951A2

  公开（公告）日：2014-01-09

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.